Kevin Strange, Ph.D., and Voot Yin, Ph.D. (IMAGE)

Novo Biosciences

Kevin Strange, Ph.D., and Voot Yin, Ph.D.

Caption

Kevin Strange, Ph.D., and Voot Yin, Ph.D., are co-founders and CEO and chief scientific officer, respectively, of Novo Biosciences, which has achieved several major milestones in its mission of bringing its breakthrough drug candidate, trodusquemine, to market as a potential regenerative medicine treatment for heart disease and Duchenne muscular dystrophy (DMD). Trodusquemine is a repurposed drug candidate that has already been shown to be well tolerated by patients.

Credit

Novo Biosciences

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.